FDA Seeks To Prevent Drug Name Confusion, While USP Develops Treatment
This article was originally published in The Tan Sheet
Executive Summary
The U.S. Pharmacopeia's new searchable drug database is designed to help consumers and caregivers avoid errors due to look-alike/sound-alike product names
You may also be interested in...
FDA’s Proposed Name Review Pilot Offers Little Reason To Participate
A proposed FDA pilot program that would shift the burden for safety review of proprietary drug names from the agency to industry needs to account for key differences between OTC and Rx products and lacks participation incentives, pharmaceutical researchers say
Pharmacy Leaflets Become Focus For Patient Safety; IoM, FDA Finalize Standards
Producers of consumer medication information leaflets are hoping that FDA provides them with more time to come into compliance with standards for usefulness, even as an Institute of Medicine report is emphasizing the need for quality in the materials
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC